Flexion Therapeutics (FLXN) Rating Lowered to Strong Sell at BidaskClub

BidaskClub downgraded shares of Flexion Therapeutics (NASDAQ:FLXN) from a sell rating to a strong sell rating in a research report report published on Saturday, BidAskClub reports.

FLXN has been the topic of several other reports. Zacks Investment Research upgraded shares of Flexion Therapeutics from a sell rating to a hold rating in a research note on Wednesday, February 6th. Wells Fargo & Co reiterated a buy rating and issued a $26.00 price target on shares of Flexion Therapeutics in a research note on Friday, December 28th. Needham & Company LLC reiterated a buy rating and issued a $36.00 price target (down from $42.00) on shares of Flexion Therapeutics in a research note on Friday, January 4th. BMO Capital Markets dropped their price target on shares of Flexion Therapeutics from $36.00 to $34.00 and set an outperform rating on the stock in a research note on Friday, January 4th. Finally, Raymond James reiterated a buy rating on shares of Flexion Therapeutics in a research note on Thursday, March 28th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Flexion Therapeutics has an average rating of Hold and an average price target of $22.64.

Shares of NASDAQ:FLXN opened at $10.63 on Friday. The company has a market capitalization of $395.86 million, a P/E ratio of -2.37 and a beta of 1.68. Flexion Therapeutics has a fifty-two week low of $9.90 and a fifty-two week high of $29.10. The company has a debt-to-equity ratio of 1.35, a quick ratio of 7.58 and a current ratio of 7.78.

In related news, insider Michael D. Clayman purchased 4,046 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were bought at an average cost of $12.36 per share, for a total transaction of $50,008.56. Following the completion of the purchase, the insider now directly owns 70,856 shares of the company’s stock, valued at approximately $875,780.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 14.59% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its position in shares of Flexion Therapeutics by 1.4% during the third quarter. BlackRock Inc. now owns 2,868,988 shares of the specialty pharmaceutical company’s stock worth $53,679,000 after acquiring an additional 39,511 shares during the last quarter. Vanguard Group Inc grew its position in shares of Flexion Therapeutics by 1.1% during the third quarter. Vanguard Group Inc now owns 1,619,112 shares of the specialty pharmaceutical company’s stock worth $30,294,000 after acquiring an additional 18,323 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Flexion Therapeutics by 1.1% during the third quarter. Vanguard Group Inc. now owns 1,619,112 shares of the specialty pharmaceutical company’s stock worth $30,294,000 after acquiring an additional 18,323 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Flexion Therapeutics during the third quarter worth approximately $23,768,000. Finally, Capital International Investors purchased a new position in shares of Flexion Therapeutics during the third quarter worth approximately $12,162,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Further Reading: Growth Stocks, What They Are, What They Are Not

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.